IncobotulinumtoxinA for the treatment of platysmal bands: a single-arm, prospective proof-of-concept clinical study.

Background: IncobotulinumtoxinA improves the appearance of facial rhytides and the aging neck.

Objective: To investigate the efficacy, safety, and subject satisfaction of incobotulinumtoxinA for platysmal band treatment.

Methods: Subjects (n = 23) with 2 to 4 platysmal bands (scoring ≥1 on a newly validated 5-point assessment scale) were enrolled.

Onset, longevity, and patient satisfaction with incobotulinumtoxinA for the treatment of glabellar frown lines: a single-arm, prospective clinical study.

Background: IncobotulinumtoxinA (Bocouture(®)) is free from complexing proteins and effective for treating glabellar frown lines.

Purpose: To determine the efficacy, onset, and duration of action of incobotulinumtoxinA for the treatment of glabellar frown lines.

Patients And Methods: In this single-arm, prospective, proof-of-concept study, 23 patients were treated with 25 U incobotulinumtoxinA, equally split between five injection sites in the glabella.

A prospective, split-face, randomized, comparative study of safety and 12-month longevity of three formulations of hyaluronic acid dermal filler for treatment of nasolabial folds.

Background: Data regarding several hyaluronic acids (HAs) used identically for facial tissue augmentation have heretofore been unavailable.

Objectives: This prospective, split-face, randomized, two-armed study sought to determine the long-term safety and effectiveness of three HAs (HA-1 (Belotero Basic/Balance), HA-2 (Restylane), and HA-3 (Juvéderm Ultra 3/Juvéderm Ultra Plus XC) in the treatment of nasolabial folds (NLFs).

Methods: Twenty participants in Arm A received HA-1 in one NLF and HA-2 in the other.